Santhera Pharmaceuticals has confirmed that the FDA has granted approval for AGAMREE® (vamorolone) oral suspension 40 mg/ml.

Clarity Pharmaceuticals,along with PSI CRO AG,have initiated an agreement and begun working on Clarity's Phase III diagnostic trial for SAR-bisPSMA involving prostate cancer applicants.

The US FDA has approved Biosyngen's BST02, a TIL therapy for liver cancer, for clinical trials.

Recently, Deciphera Pharmaceutical announced the positive top-line results of its investigational drug vimseltinib in the pivotal Phase 3 MOTION trial for patients with Tenosynovial Giant Cell Tumor (TGCT).

Recently, Pfizer announced that the third adaptation of the PD-L1 monoclonal antibody Sugemalimab has been conditionally approved by the National Medical Products Administration (NMPA) of China.

Recently, the official website of the CDE shows that the marketing authorization application for Eli Lilly's new Alzheimer's medication, donanemab, has been accepted.

Recently, Apellis Pharmaceuticals announced that The Lancet published positive 24-month results from the Phase 3 OAKS and DERBY studies evaluating Syfovre (pegcetacoplan) .

Innovent Biologics recently announced the completion of the 48-week treatment phase after reaching the primary endpoint of the phase II clinical trial in obese Chinese subjects with 9mg of the GLP-1R/GCGR dual agonist, Mazdutide.

Recently, Eli Lilly announced the long-term therapeutic effects of its investigational IL-13 inhibitor, lebrikizumab, in patients with moderate to severe atopic dermatitis.

Recently, Abbisko Therapeutics announced that its independently developed next-generation EGFR Exon20ins inhibitor ABSK112 has received approval from the NMPA of China for clinical trial applications.

Recently, KangaBio announced that its independently developed "Tumor-Specific Recombinant IL-12 Fc Fusion Protein for Injection" (pipeline code: KGX101) clinical trial application (IND) has been officially approved by the U.S. FDA.

Recently, Johnson & Johnson announced the results of its Phase 3 clinical trial for its anti-IL-23 antibody Tremfya (guselkumab) in treating moderate to severe ulcerative colitis (UC).